Cancer
Malignant Anal Neoplasm
CI-CAN-00007989Explore in graph →
Top-level68 active trials1 evidence items
Loading cancer entity…
Cancer
CI-CAN-00007989Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07192055 | Self-sampling to Optimize Anal Lesion Outcomes(SOLO) | recruiting | N/A | 572 | Medical College of WisconsinOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04713618 | Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy(GEORGIA) | active not recruiting | — | 72 | Ohio State University Comprehensive Cancer CenterOTHER | 1 |
| May 7, 2026 |
| clinicaltrials |
| NCT07029152 | Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis(SCOPE) | recruiting | N/A | 296 | Universitair Ziekenhuis BrusselOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07555678 | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer:Chase(Chase) | recruiting | Phase 2 | 241 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07407647 | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer | recruiting | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02437851 | Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection | completed | Phase 2 | 16 | AIDS Malignancy ConsortiumNETWORK | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07523152 | Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study(SAPPHIRE) | not yet recruiting | N/A | 42 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04094454 | Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy(DILANA) | recruiting | N/A | 60 | Juergen DebusOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04857528 | Detecting HPV DNA in Anal and Cervical Cancers | recruiting | — | 20 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT01858025 | Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma | completed | Early Phase 1 | 25 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06670495 | HPV Genotype Attribution and Disease Burden of Anal Cancer in China | recruiting | — | 300 | Fudan UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT05838391 | Adaptive Radiation in Anal Cancer | recruiting | N/A | 20 | Columbia UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07112690 | Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment | recruiting | N/A | 5 | Emory UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07085845 | The Self-Sampling Pilot Study(SOLOPilot) | completed | N/A | 50 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07296237 | Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer(DACG VI) | recruiting | — | 80 | Aarhus University HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06522256 | Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial(HPVsign) | recruiting | N/A | 100 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06331403 | Open Pilot Trial of a Mind-Body Sexual Well-Being Intervention for Female GI Cancer Survivors | completed | N/A | 6 | Massachusetts General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02885142 | Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?(MUCEM) | terminated | N/A | 368 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT05040815 | Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer(INSPIRE) | recruiting | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06207981 | Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA(KANALRAD) | recruiting | Phase 3 | 310 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Sep 2, 2025 | clinicaltrials |
| NCT06582849 | Enhanced Assistance During Radiotherapy for Unmet Essential Needs(EARN) | completed | N/A | 33 | Washington University School of MedicineOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06366841 | Stigma and Psychological profilE in REctal-anal caNcer pAtients(SERENA) | recruiting | — | 148 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | recruiting | — | 170 | National Cancer Institute, NaplesOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07059442 | Screening for Anal Cancer and Precancer in Women With HIV (SANCA)(SANCA) | not yet recruiting | N/A | 1,000 | Karolinska InstitutetOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02785263 | Shared Decision Making With Anal Cancer Patients on Radiation Dose(PC-Anal-01) | completed | N/A | 27 | Vejle HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03519295 | A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma(SCARCE) | completed | Phase 2 | 97 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07021378 | Tolerance to Immunomodulatory Nutritional Therapy in Oncology Patients Undergoing Chemotherapy and Radiotherapy(NESTLE) | completed | N/A | 16 | D'Or Institute for Research and EducationOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT00324415 | Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer | completed | Phase 2 | 45 | AIDS Malignancy ConsortiumNETWORK | 1 | May 30, 2025 | clinicaltrials |
| NCT03061435 | Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.(Vulvar-AIN) | recruiting | N/A | 110 | Dr. Danielle VicusOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04328740 | Phase 1 Study of Oral TP-1454 | completed | Phase 1 | 31 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06630793 | IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer(IMPAC) | recruiting | N/A | 108 | Tata Memorial CentreOTHER | 1 | Apr 8, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 12, 2026source: clinicaltrials